<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Endocr Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Endocr Soc</journal-id><journal-id journal-id-type="publisher-id">JS</journal-id><journal-id journal-id-type="pmc">JS</journal-id><journal-title-group><journal-title>Journal of the Endocrine Society</journal-title></journal-title-group><issn pub-type="epub">2472-1972</issn><publisher><publisher-name>Endocrine Society</publisher-name><publisher-loc>Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29264568</article-id><article-id pub-id-type="pmc">5686571</article-id><article-id pub-id-type="publisher-id">JS_201700244</article-id><article-id pub-id-type="doi">10.1210/js.2017-00244</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Articles</subject><subj-group subj-group-type="category-toc-heading"><subject>Parathyroid, Bone, and Mineral Metabolism</subject></subj-group></subj-group></article-categories><title-group><article-title>Acute Homeostatic Changes Following Vitamin D<sub>2</sub> Supplementation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Berg</surname><given-names>Anders H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bhan</surname><given-names>Ishir</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Powe</surname><given-names>Camille</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karumanchi</surname><given-names>S. Ananth</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Dihua</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thadhani</surname><given-names>Ravi I.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215</aff><aff id="aff2"><label>2</label>Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114</aff><aff id="aff3"><label>3</label>Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114</aff><aff id="aff4"><label>4</label>Division of Nephrology and Center for Vascular Biology Research, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215</aff></contrib-group><author-notes><corresp id="cor1">Address all correspondence to: Anders H. Berg, MD, PhD, Beth Israel Deaconess Medical Center, 330 Brookline Avenue YA309, Boston, Massachusetts 02115. E-mail: <email>ahberg@bidmc.harvard.edu</email>.</corresp></author-notes><pub-date pub-type="collection"><day>01</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>19</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>7</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>1</volume><issue>9</issue><fpage>1135</fpage><lpage>1149</lpage><history><date date-type="received"><day>05</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Endocrine Society</copyright-statement><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><self-uri xlink:title="pdf" content-type="pdf" xlink:href="js-01-1135.pdf"/><abstract><sec id="s1"><title>Context:</title><p>Changes in vitamin D binding protein (DBP) concentrations and catabolism of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D (24,25D) after vitamin D2 supplementation may alter concentrations and bioavailability of circulating 25-hydroxyvitamin D (25D).</p></sec><sec id="s2"><title>Objective:</title><p>Examine acute changes in vitamin D metabolism and bioavailability after vitamin D2 supplementation.</p></sec><sec id="s3"><title>Methods:</title><p>Study design was secondary analysis of a single-arm interventional study. Thirty consenting volunteers were treated with five 50,000 IU oral doses of ergocalciferol over 2 weeks. Main outcome measures included concentrations of DBP, vitamin D metabolites, and bioavailable 25-hydroxyvitamin D (25D) in pre- and posttreatment serum samples.</p></sec><sec id="s8"><title>Results:</title><p>After supplementation, 25D<sub>2</sub> (mean &#x000b1; standard deviation) increased from 1.4 &#x000b1; 0.9 ng/mL to 45.3 &#x000b1; 16.5 ng/mL (<italic>P</italic> &#x0003c; 0.0001), and 25D<sub>3</sub> levels decreased from 26.8 &#x000b1; 9.9 ng/mL to 19.7 &#x000b1; 8.2 ng/mL (<italic>P</italic> &#x0003c; 0.0001). Total 25D (25D<sub>2</sub> plus 25D<sub>3</sub>) increased from 28.2 &#x000b1; 10.0 ng/mL to 65.0 &#x000b1; 21.1 ng/mL (152.2% &#x000b1; 102.5%; <italic>P</italic> &#x0003c; 0.0001). DBP and total 24,25D concentrations increased 39.1% &#x000b1; 39.4% (165.6 &#x000b1; 53.8 &#x000b5;g/mL to 222.0 &#x000b1; 61.1 &#x000b5;g/mL; <italic>P</italic> &#x0003c; 0.0001) and 31.3% &#x000b1; 48.9% (3.9 &#x000b1; 2.0 ng/mL to 4.7 &#x000b1; 2.1 ng/mL; <italic>P</italic> = 0.0147), respectively. In contrast to total 25D, bioavailable 25D increased by 104.4% &#x000b1; 99.6% (from 5.0 &#x000b1; 2.0 ng/mL to 8.7 &#x000b1; 2.7 ng/mL; <italic>P</italic> &#x0003c; 0.001), and 1,25D increased by 32.3% &#x000b1; 38.8% (from 45.5 &#x000b1; 10.7 pg/mL to 58.1 &#x000b1; 13.0 pg/mL; <italic>P</italic> = 0.0006). There were no changes in calcium or parathyroid hormone (<italic>P</italic> &#x0003e; 0.05 for both).</p></sec><sec id="s9"><title>Conclusion:</title><p>Changes after vitamin D2 supplementation involve acute rise in serum DBP and 24,25D, both of which may attenuate the rise in bioavailable 25D and 1,25D.</p></sec></abstract><abstract abstract-type="teaser"><p>After 2 weeks of treatment with vitamin D2, serum levels of vitamin D binding protein and 24,25-dihydroxyvitamin D increased, which may decrease the bioavailability and half-life of vitamin D metabolites.</p></abstract><kwd-group><kwd>24,25-dihydroxyvitamin D</kwd><kwd>25-hydroxvitamin D</kwd><kwd>ergocalciferol supplementation</kwd><kwd>feedback regulation</kwd><kwd>vitamin D binding protein</kwd></kwd-group><counts><fig-count count="5"/><table-count count="2"/><equation-count count="0"/><ref-count count="74"/><page-count count="15"/></counts></article-meta></front><body><p>Vitamin D deficiency has been associated with several adverse health outcomes, including abnormal bone mineralization, heart disease, and premature mortality [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. Conversely, hypervitaminosis D has been linked with hypercalcemia, tissue calcinosis, and renal injury [<xref rid="B9" ref-type="bibr">9</xref>]. In response to variations in exposure (<italic>e.g.,</italic> sunlight, diet) and exogenous supplementation, counter regulatory mechanisms are in place that maintain appropriate concentrations of 1,25-hydroxyvitamin D (1,25D) and its precursor 25-dihydroxyvitamin D (25D) [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. As with other hormones, feedback loops involve anabolic and catabolic pathways [<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>] that modify levels of bioavailable forms of the hormone [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>].</p><p>Changes in levels of binding proteins and, consequently, changes in bioavailable levels of hormones are well-known endocrine regulatory mechanisms [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>]. Vitamin D binding protein (DBP) is a circulating binding protein for both 25D and 1,25D [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>] and an important determinant of 25D concentrations in the circulation that likely regulates the bioavailability of 25D and 1,25D to target tissues [<xref rid="B16" ref-type="bibr">16</xref>]. The determinants of DBP concentrations in humans, however, are incompletely understood. Both 25D and DBP are synthesized and secreted by the liver, and because of the high binding affinity of DBP for 25D, most circulating 25D is tightly bound to DBP [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B30" ref-type="bibr">30</xref>]. Humans with liver disease demonstrate low blood levels of DBP, and accordingly low total 25D levels, but exhibit normal bioavailable or free serum 25D levels [<xref rid="B31" ref-type="bibr">31</xref>]. In contrast, excess DBP results in lower bioavailable levels. For example, in tissue culture models of vitamin D receptor signaling, exogenous addition of DBP to culture media dramatically reduces bioavailability of both 25D and 1,25D [<xref rid="B16" ref-type="bibr">16</xref>]. It is unknown, however, whether and to what extent vitamin D supplementation affects DBP levels following routine supplementation.</p><p>A second mechanism that allows vitamin D target tissue to modulate vitamin D signaling is by regulating expression of enzymes that convert 25D to it active form (1,25D) and to its inactive catabolite [24,25-dihydroxyvitamin D (24,25D)]. Conversion of circulating 25D to 1,25D occurs primarily in the kidneys and is upregulated during states of vitamin D deficiency [<xref rid="B32" ref-type="bibr">32</xref>]. In contrast, 25-hydroxyvitamin D 24-hydroxylase (CYP24A1) is highly expressed in the kidney and converts 1,25D and 25D to the inactive metabolites 1,24,25-trihydroxyvitamin D and 24,25D, respectively [<xref rid="B32" ref-type="bibr">32</xref>]. CYP24A1 is thus an efficient suppressor of vitamin D signaling by depleting both the active form of vitamin D (1,25D) and its precursor (25D).</p><p>We hypothesized that acute administration of high doses of vitamin D<sub>2</sub> would lead to counter regulatory changes in circulating DBP and expression of CYP24A1 and CYP27B1 that, in turn, would lead to sequential alterations in the bioavailability of 25D and its conversion to the active 1,25-dihydroxy form (<xref ref-type="fig" rid="F1">Fig 1</xref>). Given the evidence of multiple mechanisms regulating vitamin D signaling, including the influence of DBP on concentrations of bioavailable 25D, it is likely that there is reciprocal regulation of blood concentrations of DBP after administration of vitamin D supplements, which may be an important feedback mechanism for maintaining appropriate concentrations of 1,25 D. Similar feedback regulatory changes in binding proteins have been described in other hormonal systems (<italic>e.g.</italic>, increases in sex hormone&#x02013;binding globulin after administration of estrogen) [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>]. In this study, we examined the short-term changes of circulating concentrations of DBP, 24,25D, and bioavailable 25D after acute treatment of subjects with high doses of ergocalciferol (vitamin D<sub>2</sub>).</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Model for regulated sequential conversion of vitamin D to its active form, and clinical conditions known to alter these steps. &#x02191;, increased; VDR, vitamin D receptor.</p></caption><graphic xlink:href="js-01-1135-f1"/></fig><sec id="s10"><title>1. Materials and Methods</title><sec id="s11"><title>A. Study Design and Participants</title><p>One hundred healthy adults (age &#x02265;18 years) were recruited using both hard-copy and online advertisements. The study was conducted at the Massachusetts General Hospital from July 2007 to January 2012. Subjects were excluded if they had a known history of kidney disease, nephrolithiasis, or hypercalcemia. Exclusion criteria also included exposure to an active vitamin D analog (<italic>e.g.</italic>, calcitriol, doxercalciferol, or paricalcitol) within 30 days, use of immunomodulatory or immunosuppressive medications, pregnancy, known or suspected active infectious processes, or known granulomatous diseases. Candidates who signed written informed consent underwent screening laboratory testing including serum 25D, calcium, phosphorus, and serum creatinine levels; and urine pregnancy testing. Estimated glomerular filtration rate was calculated using the simplified Modification of Diet in Renal Disease equation [<xref rid="B35" ref-type="bibr">35</xref>]. Subjects with serum levels of calcium &#x0003e;10.5 mg/dL and phosphorus &#x0003e;5 mg/dL, a positive urine pregnancy test, or an estimated glomerular filtration rate &#x0003c;60 mL/min were excluded from further participation. All eligible participants with serum 25D level &#x02264;32 ng/mL were offered treatment with 50,000 IU ergocalciferol taken orally every other day for five total doses (250,000 IU) over 2 weeks.</p><p>This study represents a secondary analysis of the original aims, which were intended to examine the relationship of vitamin D levels and cathelicidin [<xref rid="B36" ref-type="bibr">36</xref>]. The study was conducted in compliance with the Declaration of Helsinki principles, approved by the institutional review boards of Massachusetts General Hospital and the Massachusetts Institute of Technology, and registered with ClinicalTrials.gov (NCT00742235).</p></sec><sec id="s12"><title>B. Data Collection</title><p>Subjects were screened for eligibility and, after consent and enrollment, a blood sample was collected before their first dose of ergocalciferol. Subjects were seen again 2 weeks later, after their final dose of ergocalciferol, when a final follow-up blood sample was obtained. For this study, baseline and posttreatment blood samples were analyzed for DBP, 25-hydroxyvitamin D<sub>2</sub> (25D<sub>2</sub>), 25-hydroxyvitamin D<sub>3</sub> (25D<sub>3</sub>), 1,25D, 24,25-dihydroxyvitamin D<sub>2</sub> (24,25D<sub>2</sub>), 24,25-dihydroxyvitamin D<sub>3</sub> (24,25D<sub>3</sub>), parathyroid hormone (PTH), calcium, phosphorous, and albumin concentrations. Vital signs including heart rate, temperature, and blood pressure were measured and recorded at both visits.</p></sec><sec id="s13"><title>C. Biochemical Analyses</title><p>Blood samples were drawn into serum separator tubes without anticoagulant, centrifuged at 1430<italic>g</italic> for 15 minutes, and stored at &#x02212;80&#x000b0;C for future analysis. To screen subjects for eligibility, baseline blood samples were tested for total 25D using a US Food and Drug Administration-approved immunoassay within a Clinical Laboratory Improvement Amendments-certified hospital laboratory.</p><p>To measure pre- and postsupplementation serum concentrations of 25D<sub>3</sub>, 24,25D<sub>3</sub>, 25D<sub>2</sub>, and 24,25D<sub>2</sub>, serum samples were subsequently tested using liquid chromatography&#x02013;tandem mass spectrometry (LC-MS/MS). For these analyses, 100 &#x000b5;L of serum was mixed with 25D<sub>3</sub>&#x02013;[<sup>2</sup>H<sub>6</sub>] and 24,25-(OH)<sub>2</sub>D<sub>3</sub>&#x02013;[<sup>2</sup>H<sub>6</sub>] isotopic internal standards dissolved in 5% bovine serum albumin (IsoSciences, King of Prussia, PA), and 25D<sub>3,</sub> 25D<sub>2</sub>, 24,25D<sub>3</sub>, and 24,25D<sub>2</sub> were isolated by solid-phase extraction (Strata C-18E 96-well SPE plates; Phenomenex, Torrence, CA), eluted with acetonitrile, and derivatized with 4-phenyl-1,2,4-triazole-3,5-dione. Samples were vacuum lyophilized and redissolved with 100 &#x000b5;L of 50% ethanol. Samples were then analyzed for vitamin D metabolites using reverse-phase chromatography coupled to tandem mass spectrometry in multiple reaction monitoring mode [intra-assay coefficients of variation (CVs): 1.1%, 1.3%, 3.5%, and 4.2% for 25D<sub>3</sub>, 25D<sub>2</sub>, 24,25D<sub>3</sub>, and 24,25D<sub>2</sub>, respectively]. Assays were calibrated using 25D3 and 25D2 certified reference standards (Cerilliant, Round Rock, TX; accuracy traceable to National Institute of Standards and Technology SRM 2972 reference material), 24R,25-(OH)<sub>2</sub>D<sub>3</sub> standard from Santa Cruz Biotechnology (Santa Cruz, CA), 24R,25-(OH)<sub>2</sub>D<sub>2</sub> standard from Sigma-Aldrich (St. Louis, MO). Complete descriptions of chromatography and mass spectrometer settings have been previously described [<xref rid="B37" ref-type="bibr">37</xref>]. Intact serum PTH was measured using the Cobas electrochemiluminescence immunoassay on the Modular Analytics E170 automated analyzer (Roche Diagnostics, Indianapolis, IN; interassay CV, 2.5%).</p><p>Serum levels of 1,25D were measured in the 28 subjects with remaining sample by immunoassay on the Diasorin platform (Stillwater, MN; inter- and intra-assay CVs, &#x0003c;7.5%, validated against multiple clinical assay methods as previously described in [<xref rid="B38" ref-type="bibr">38</xref>]). Serum albumin and calcium levels were measured by colorimetric assay on automated platforms in a Clinical Laboratory Improvement Amendments-certified hospital laboratory. Serum fibroblast growth factor-23 (FGF23) was measured in pre- and posttreatment samples from the 24 subjects with remaining sample using the second generation human FGF23 (C-term) enzyme-linked immunosorbent assay kit (catalog no. 60-6100) from Immutopics (San Clemente, CA), using the manufacturer&#x02019;s instructions.</p><p>Calculation of bioavailable 25D (defined as the sum of free and albumin-bound 25D) was performed using methods we have previously described [<xref rid="B39" ref-type="bibr">39</xref>]. Briefly, total 25D is calculated from the sum of 25D<sub>3</sub> and 25D<sub>2</sub> concentrations; concentrations of free, DBP-bound, and albumin-bound 25D are calculated based on previously estimated binding affinity constants [<xref rid="B20" ref-type="bibr">20</xref>]; and concentrations of bioavailable 25D are calculated by summing the concentrations of free and albumin-bound 25D. To corroborate results obtained by calculated bioavailable 25D measurements, bioavailable 25D was also measured using a direct assay method described in <inline-supplementary-material xlink:href="js-01-1135-sm1.pdf" id="d35e553" content-type="local-data">Supplemental Materials</inline-supplementary-material>. The direct assay for bioavailable 25D was calibrated using standards composed of buffered saline, 5% bovine serum albumin, and varying amounts purified vitamin D binding protein (Sigma-Aldrich). Calculated and direct bioavailable assay values were highly correlated with each other (<italic>R</italic><sup>2</sup> = 0.6901; <italic>P</italic> &#x0003c; 0.0001; <inline-supplementary-material xlink:href="js-01-1135-sm1.pdf" id="d35e565" content-type="local-data">Supplemental Fig 1</inline-supplementary-material>).</p><sec id="s14"><title>C-1. Mass spectrometric measurement of DBP</title><p>DBP was measured using two different assays, both involving high-performance liquid chromatography and tandem mass spectrometry. Serum from each subject (3 &#x003bc;L) was first mixed with 3 &#x003bc;L of DBP internal standard. The internal standard was composed of bovine DBP purified from fetal calf serum using Cohn ethanol fractionation followed by anion-exchange chromatography.</p><p>In the first LC-MS/MS assay method, premixed subject serum and DBP internal standard were diluted into 50 &#x003bc;L of protease digestion mixture composed of 50 &#x003bc;L of 25 mM Tris-HCl, pH 7.4, 10 mM dithiothreitol, and 0.1 mg/mL glutamyl endoproteinase (Worthington Biochemical, Lakewood, NJ), and digested overnight at 37&#x000b0;C. Human and bovine DBPs were then analyzed and quantified by LC-MS/MS. In the second LC-MS/MS assay, which was very similar to a recently published method [<xref rid="B40" ref-type="bibr">40</xref>], 3 &#x003bc;L of serum was mixed with DBP internal standard, denatured and reduced with trifluoroethanol and dithiothreitol, and alkylated with iodoacetamide. Denatured samples were then digested overnight at 37&#x000b0;C in 25 mM Tris-HCl, pH 7.4, with 0.1 mg/mL tosyl phenylalanyl chloromethyl ketone-modified trypsin (Worthington Biochemical). After digestion with either Glu-C or trypsin, 10 &#x003bc;L of the resulting digested serum peptides were injected and resolved by reverse-phase chromatography on a Kinetex C18 column, 50 &#x000d7; 3 mm, 5-&#x000b5;m bead diameter (Phenomenex) eluted with 0.1% formic acid and 0% to 100% acetonitrile gradient. Digested peptides specific for the human and bovine DBP were measured using multiple reaction monitoring using settings shown in <inline-supplementary-material xlink:href="js-01-1135-sm1.pdf" id="d35e578" content-type="local-data">Supplemental Table 1</inline-supplementary-material>. Assay characteristics are described in <inline-supplementary-material xlink:href="js-01-1135-sm1.pdf" id="d35e581" content-type="local-data">Supplemental Figs 2&#x02013;4</inline-supplementary-material>.</p><p>The peptides used to quantify DBP for both assay methods are digested peptides common to DBP protein variants Gc1S, Gc1F, and Gc2, and thus quantify total serum DBP concentrations including all major variants. The peptides used to quantify the internal standard for both methods are the homologous peptides liberated by digestion within bovine DBP. Purified DBP calibrators were purchased from Sigma-Aldrich (Gc-globulin, catalog no. G8764). Aliquots of pooled serum frozen at &#x02212;80&#x000b0;C were used to monitor interassay quality control; the CV of the assay was 6.2%.</p><p>All LC-MS/MS assays were performed using an API 5000 triple quadrupole mass spectrometer (SCIEX, Framingham, MA) interfaced with a Shimadzu ultra&#x02013;high-pressure liquid chromatography system with autosampler (Shimadzu USA, Columbia, MD). Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich.</p></sec></sec><sec id="s15"><title>D. Statistical Analysis</title><p>Baseline data were summarized using means, standard deviations, medians, and interquartile ranges. Frequencies were computed for all categorical and ordinal variables. Laboratory parameters were compared using pairwise <italic>t</italic> tests or Wilcoxon tests, depending upon the normality of the data. Correlation analyses were reported using the Pearson correlation coefficient. The statistical significance was set at a two-sided <italic>P</italic> &#x0003c; 0.05. All analyses were performed with R version 3.2.2 (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>).</p></sec></sec><sec id="s16"><title>2. Results</title><sec id="s17"><title>A. Subject Characteristics</title><p>Of the 36 subjects offered oral ergocalciferol supplementation, 30 completed the study; three were excluded due to inadequate sample, and three were excluded due to noncompliance based on the absence of detectable 25D<sub>2</sub> in their posttreatment samples (<xref ref-type="fig" rid="F2">Fig 2</xref>). Baseline characteristics of the 30 subjects are shown in <xref ref-type="table" rid="T1">Table 1</xref>. Most were white, normotensive, and had normal renal function. Baseline levels of serum calcium, parathyroid hormone, and albumin were also within normal limits. As shown in <xref ref-type="table" rid="T2">Table 2</xref>, the mean baseline serum concentration of vitamin 25D<sub>3</sub> was 26.8 &#x000b1; 9.9 ng/mL (range, 9.6&#x02013;44.7 ng/mL), mean baseline serum concentration of 25D<sub>2</sub> was 1.4 &#x000b1; 0.9 ng/mL (range, 0.4&#x02013;4.2 ng/mL), and mean concentration of 24,25D<sub>3</sub> was 3.9 &#x000b1; 2.0 ng/mL (range, 0.81&#x02013;8.17 ng/mL). The subjects included in the study all had baseline total 25D level &#x0003c;32 ng/mL when tested by immunoassay during screening for eligibility, but a few were found to have baseline values &#x0003e;32 ng/mL when subsequently tested by LC-MS/MS. This is most likely due to the poorer precision and negative bias that have been previously described for clinical immunoassays [<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>]. The mean baseline concentration of serum DBP among subjects was 165.6 &#x000b1; 53.8 &#x000b5;g/mL (range, 105.7&#x02013;323.0 &#x000b5;g/mL). Correlations between baseline PTH and total 25D<sub>3</sub> and baseline PTH and bioavailable 25D<sub>3</sub> were &#x02212;0.411 (<italic>P</italic> = 0.02) and &#x02212;0.413 (<italic>P</italic> = 0.02), respectively.</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Consort diagram.</p></caption><graphic xlink:href="js-01-1135-f2"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p><bold>Subjects&#x02019; Baseline Characteristics</bold></p></caption><table frame="above" rules="groups"><col width="56.72" span="1"/><col width="43.28" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Characteristic</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Data (N = 30 subjects)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, y</td><td valign="top" align="center" rowspan="1" colspan="1">30.7 (25.9 &#x02013; 49.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male sex</td><td valign="top" align="center" rowspan="1" colspan="1">53 (16)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;White</td><td valign="top" align="center" rowspan="1" colspan="1">60 (18)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Black</td><td valign="top" align="center" rowspan="1" colspan="1">13.3 (4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Asian</td><td valign="top" align="center" rowspan="1" colspan="1">13.3 (4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Other</td><td valign="top" align="center" rowspan="1" colspan="1">13.3 (4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hispanic ethnicity</td><td valign="top" align="center" rowspan="1" colspan="1">23.3 (7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Never smoked</td><td valign="top" align="center" rowspan="1" colspan="1">46.7 (14)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">24.3 (22.7&#x02013;28.4)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data reported as median (interquartile range) or percentage of total (no.).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p><bold>Changes in Laboratory Parameters Pre- and Posttreatment With High-Dose Oral Ergocalciferol</bold></p></caption><table frame="above" rules="groups"><col width="36.2" span="1"/><col width="16.63" span="1"/><col width="16.92" span="1"/><col width="10.64" span="1"/><col width="19.61" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Standard Vitamin D Parameters</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Pretreatment</bold><bold>*</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Posttreatment</bold><bold>*</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>P</italic></bold><sup><xref ref-type="table-fn" rid="t2n1"><bold><italic>a</italic></bold></xref></sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Average % Change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">25D<sub>2</sub>, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 &#x000b1; 0.9</td><td valign="top" align="center" rowspan="1" colspan="1">45.3 &#x000b1; 16.5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">4926 &#x000b1; 4622</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">25D<sub>3</sub>, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">26.8 &#x000b1; 9.9</td><td valign="top" align="center" rowspan="1" colspan="1">19.7 &#x000b1; 8.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;25.0 &#x000b1; 25.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total 25D, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">28.2 &#x000b1; 10.0</td><td valign="top" align="center" rowspan="1" colspan="1">65.0 &#x000b1; 21.1</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">152.2 &#x000b1; 102.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bioavailable 25D, calculated, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">5.0 &#x000b1; 2.0</td><td valign="top" align="center" rowspan="1" colspan="1">8.7 &#x000b1; 2.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">104.4 &#x000b1; 99.6</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bioavailable 25D, direct assay, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">3.4 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">5.6 &#x000b1; 0.4</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">99 &#x000b1; 21</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1,25D, pg/mL</td><td valign="top" align="center" rowspan="1" colspan="1">45.5 &#x000b1; 10.7</td><td valign="top" align="center" rowspan="1" colspan="1">58.1 &#x000b1; 13.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.0006</td><td valign="top" align="center" rowspan="1" colspan="1">32.3 &#x000b1; 38.8</td></tr><tr><td colspan="2" valign="top" align="left" scope="col" rowspan="1">Compensatory responses</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;DBP (GluC method), &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">165.6 &#x000b1; 53.8</td><td valign="top" align="center" rowspan="1" colspan="1">222.0 &#x000b1; 61.1</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">39.1 &#x000b1; 39.4</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;DBP (trypsin method), &#x000b5;g/mL</td><td valign="top" align="center" rowspan="1" colspan="1">156.2 &#x000b1; 54.0</td><td valign="top" align="center" rowspan="1" colspan="1">189.3 &#x000b1; 52.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.015</td><td valign="top" align="center" rowspan="1" colspan="1">26.3 &#x000b1; 38.9</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;24,25D<sub>2</sub>, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">0.05 &#x000b1; 0.03</td><td valign="top" align="center" rowspan="1" colspan="1">0.91 &#x000b1; 0.38</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">2835.5 &#x000b1; 2557.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;24,25D<sub>3</sub>, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">3.8 &#x000b1; 2.0</td><td valign="top" align="center" rowspan="1" colspan="1">3.8 &#x000b1; 1.9</td><td valign="top" align="center" rowspan="1" colspan="1">0.8042</td><td valign="top" align="center" rowspan="1" colspan="1">3.3 &#x000b1; 40.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Total 24,25D, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">3.9 &#x000b1; 2.0</td><td valign="top" align="center" rowspan="1" colspan="1">4.7 &#x000b1; 2.1</td><td valign="top" align="center" rowspan="1" colspan="1">0.0147</td><td valign="top" align="center" rowspan="1" colspan="1">31.3 &#x000b1; 48.9</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;24,25D<sub>3</sub>:25D<sub>3</sub> ratio</td><td valign="top" align="center" rowspan="1" colspan="1">0. 14 &#x000b1; 0.04</td><td valign="top" align="center" rowspan="1" colspan="1">0.19 &#x000b1; 0.04</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td valign="top" align="center" rowspan="1" colspan="1">40.6 &#x000b1; 41.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;24,25D<sub>2</sub>:25D<sub>2</sub> ratio</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.021 &#x000b1; 0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Minerals and hormones</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Calcium, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">9.4 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">9.4 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.76</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.1 &#x000b1; 3.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Phosphate, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">3.5 &#x000b1; 0.5</td><td valign="top" align="center" rowspan="1" colspan="1">3.6 &#x000b1; 0.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.20</td><td valign="top" align="center" rowspan="1" colspan="1">4.1 &#x000b1; 14.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Albumin, g/dL</td><td valign="top" align="center" rowspan="1" colspan="1">4.6 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">4.6 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.45</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.6 &#x000b1; 5.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Parathyroid hormone, pg/mL</td><td valign="top" align="center" rowspan="1" colspan="1">47.3 &#x000b1; 16.7</td><td valign="top" align="center" rowspan="1" colspan="1">47.6 &#x000b1; 19.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.91</td><td valign="top" align="center" rowspan="1" colspan="1">5.4 &#x000b1; 40.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Fibroblast growth factor-23, IU/mL</td><td valign="top" align="center" rowspan="1" colspan="1">36.1 &#x000b1; 34.4</td><td valign="top" align="center" rowspan="1" colspan="1">26.5 &#x000b1; 25.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.10</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;25 &#x000b1; 170</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data reported as mean &#x000b1; standard deviation.</p></fn><fn id="t2n1"><label><sup>a</sup></label><p><italic>P</italic> values indicate statistical significance of difference between pre- and posttreatment average values by pairwise <italic>t</italic> test or pairwise Wilcoxon test, whichever was appropriate.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s18"><title>B. Acute Homeostatic Changes in Vitamin D Metabolites</title><p><xref ref-type="table" rid="T2">Table 2</xref> summarizes the changes in levels of standard vitamin D measures, compensatory changes in the vitamin D metabolites, and calcium, phosphate, albumin, PTH, and FGF23 levels after a cumulative dose of 250,000 units of ergocalciferol over 2 weeks (22.3 times the recommended dose of 800 IU per day [<xref rid="B45" ref-type="bibr">45</xref>]). The marked rise in levels of 25D<sub>2</sub> was reflected in a significant rise in total 25D levels (152%). Changes in concentrations of total 25D within individual subjects are depicted in <inline-supplementary-material xlink:href="js-01-1135-sm1.pdf" id="d35e1036" content-type="local-data">Supplemental Fig 5</inline-supplementary-material>. When concentrations of bioavailable 25D were calculated based on measured total 25D, albumin, and DBP concentrations, bioavailable 25D was found to have increased by 104%. When we measured concentrations of bioavailable 25D using a newly developed direct binding assay, bioavailable 25D was found to have increased by 99%, corroborating the results of the calculated bioavailable 25D measurements. Last, concentrations of 1,25D measured by immunoassay (D<sub>2</sub> and D<sub>3</sub> combined) increased by only 32%.</p><p>After 2 weeks of supplementation with ergocalciferol, mean circulating DBP concentrations increased approximately 39%, from 165.6 &#x000b1; 53.8 &#x000b5;g/mL to 222.0 &#x000b1; 61.1 &#x000b5;g/mL (<italic>P</italic> &#x0003c; 0.0001). Changes in concentrations of DBP within individual subjects are depicted in <inline-supplementary-material xlink:href="js-01-1135-sm1.pdf" id="d35e1050" content-type="local-data">Supplemental Fig 6</inline-supplementary-material>. DBP measured using the second LC-MS/MS assay method also demonstrated a significant increase in DBP concentrations after ergocalciferol supplementation, from 156.2 &#x000b1; 54.0 &#x000b5;g/mL to 189.3 &#x000b1; 52.6 &#x000b5;g/mL (<italic>P</italic> = 0.015). Note that DBP measurements between the two assays were strongly correlated and in close agreement (<italic>R</italic><sup>2</sup> = 0.8088; <inline-supplementary-material xlink:href="js-01-1135-sm1.pdf" id="d35e1061" content-type="local-data">Supplemental Fig 4</inline-supplementary-material>). There was a significant correlation between serum DBP and 1,25D concentrations after vitamin D<sub>2</sub> supplementation, suggesting a relationship between the rise in 1,25D and DBP concentrations (<xref ref-type="fig" rid="F3">Fig 3</xref>). After supplementation, there was a corresponding increase in serum concentrations of the breakdown metabolite 24,25D<sub>2</sub> and an overall increase of 24,25D by approximately 31% (<xref ref-type="table" rid="T2">Table 2</xref>). Furthermore, a strong correlation between 24,25D<sub>2</sub> and 25D<sub>2</sub> was observed (<xref ref-type="fig" rid="F4">Fig 4</xref>).</p><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Correlations between serum DBP and 1,25D concentrations before and after vitamin D<sub>2</sub> supplementation. (a) Pretreatment. (b) Posttreatment. Pearson correlation coefficient and <italic>P</italic> values are shown.</p></caption><graphic xlink:href="js-01-1135-f3"/></fig><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Linear relationships between serum concentrations of 24,25D<sub>2</sub> and 25D<sub>2</sub> after vitamin D2 supplementation. Linear regression trendlines and Pearson correlation coefficients are shown.</p></caption><graphic xlink:href="js-01-1135-f4"/></fig><p>Although there was no change in subjects&#x02019; diets or sun exposure during the 2-week study period, concentrations of 25D<sub>3</sub> decreased by 25% after supplementation with ergocalciferol. Despite the decrease in concentrations of 25D<sub>3</sub>, concentrations of its metabolite 24,25D<sub>3</sub> did not decrease and, as a consequence, there was a 41% increase in the ratio of 24,25D<sub>3</sub> to 25D<sub>3</sub>. The decrease in 25D<sub>3</sub> concentrations relative to 24,25D<sub>3</sub> was also reflected by a shift to the left in the linear relationship between 24,25D<sub>3</sub> and 25D<sub>3</sub> after supplementation (<xref ref-type="fig" rid="F5">Fig 5</xref>). Together, these findings are highly suggestive of an increase in CYP24A1 activity, which would result in increased production of 24,25D<sub>3</sub> despite the simultaneous catabolism (and loss) of 25D<sub>3.</sub></p><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Linear relationships between serum concentrations of 24,25D<sub>3</sub> and 25D<sub>3</sub> before (circles) and after (triangles) vitamin D<sub>2</sub> supplementation. Linear regression trendlines and Pearson correlation coefficients are shown.</p></caption><graphic xlink:href="js-01-1135-f5"/></fig><sec id="s19"><title>B-1. Minerals, PTH, and FGF23</title><p>Serum levels of calcium, PTH, and albumin were normal at baseline and did not significantly change after supplementation with ergocalciferol (<italic>P</italic> &#x0003e; 0.05 for all comparisons). Concentrations of FGF23 also did not show any significant changes after ergocalciferol treatment (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec></sec></sec><sec id="s20"><title>3. Discussion</title><p>Our results suggest that physiologic changes after oral vitamin D<sub>2</sub> supplementation involve an acute increase in circulating DBP levels that may attenuate the rise in bioavailable 25D levels, as well as a parallel rise in 24,25D levels, whose production reflects an increased catabolism of 25D by CYP24A1.Upregulation of CYP24A1 would also be predicted to attenuate the rise of the active metabolite 1,25D. This may explain why healthy subjects with relatively normal levels of vitamin D and normal levels of serum calcium do not become hypercalcemic after receiving high doses of vitamin D<sub>2</sub>.</p><p>DBP is the major carrier protein for circulating 25D, with estimated dissociation constants in the low nanomolar range [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>]. The high binding affinity of DBP makes it the major carrier for 25D but also results in reduction of the concentrations of free and bioavailable 25D [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B24" ref-type="bibr">24</xref>], analogous to the effects of thyroid hormone&#x02013;binding globulin on thyroid hormone bioavailability [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>]. It has been hypothesized that DBP is essential for delivery of 25D to the kidney via megalin-mediated uptake in the proximal tubules [<xref rid="B48" ref-type="bibr">48</xref>]. Cell culture studies, however, confirm that DBP limits uptake of 25D and 1,25D by cells, thus acting as a key regulator of bioavailability of 25D for conversion and bioavailability of 1,25D for signaling [<xref rid="B16" ref-type="bibr">16</xref>]. Furthermore, mice genetically deficient for DBP develop profoundly decreased circulating 25D concentrations but are free from any ill effects of vitamin D deficiency while receiving a vitamin D-replete diet, presumably because of adequate bioavailable 25D levels due to the absence of DBP [<xref rid="B24" ref-type="bibr">24</xref>]. As a corollary, patients with DBP deficiency secondary to liver disease, as well as women with low DBP concentrations associated with estrogen deficiency after menopause, have low total 25D levels but normal bioavailable or free 25D levels [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>]. Our data support the cell culture studies in that the rise in DBP after vitamin D supplementation attenuated the increase in bioavailable 25D and 1,25D levels, compared with the dramatic rise of total 25D (104% and 32%, vs 152%).</p><p>After treatment with ergocalciferol, DBP concentrations increased significantly and were also correlated with concentrations of 1,25D. Increases in levels of circulating DBP in patients after vitamin D supplementation have been reported by others. In one study of patients with both hip fracture and vitamin D deficiency, it was found that 3 months of treatment with either cholecalciferol or ergocalciferol produced significant increases in serum DBP concentrations [<xref rid="B51" ref-type="bibr">51</xref>]. A similar pattern has been seen in women given estrogens or women during pregnancy; following increases in estrogen, the concentrations of 1,25D increased, and concentrations of DBP increased in parallel with 1,25D [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>]. The increase in DBP levels after introduction of exogenous vitamin D and increased 1,25D signaling is analogous to the increase in sex hormone&#x02013;binding globulin levels in patients treated with exogenous estrogen [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>]. Together, these observations suggest that production of DBP may be directly induced by increased activation of vitamin D receptor by 1,25D (<xref ref-type="fig" rid="F1">Fig 1</xref>). Although it may be premature to conclude that our observations offer definitive evidence of a physiologic mechanism for regulation of vitamin D activity, our data suggest that the observed rise in DBP after vitamin D supplementation may be acting to attenuate the rise in 1,25D levels.</p><p>In addition to the effects of vitamin D<sub>2</sub> supplementation on serum concentrations of DBP, we also observed coordinated changes in 25D catabolism. Although there were no changes in the diet or sun exposure of the subjects, average concentrations of 25D<sub>3</sub> decreased significantly among the subjects, while average concentrations of its downstream metabolite 24,25D<sub>3</sub> did not decrease. Because production of 24,25D depend on the concentration of its precursor 25D, we would normally expect 24,25D concentrations to decrease proportionally to the decrease in 25D level (this decrease in 24,25D relative to 25D should be further amplified by the fact that the half-life of 25D<sub>3</sub> is approximately 55.7-fold longer than that of 24,25D<sub>3</sub> [<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>]). As a consequence of these changes, we observed that the average ratio of 24,25D3 to 25D3 and the linear relationship between 24,25D3 and 25D3 (<xref ref-type="fig" rid="F5">Fig 5</xref>) increased significantly after vitamin D<sub>2</sub> supplementation. All these findings suggest a change in the equilibrium between 24,25D3 and its precursor 25D<sub>3</sub> after the subjects received vitamin D<sub>2</sub> supplements. Together, these findings are most easily explained by an increase in the conversion of 25D to 24,25D by CYP24A1. If we accept this explanation, then the increase in catabolism of 25D<sub>3</sub> to 24,25D<sub>3</sub> further provides an explanation of why concentrations of 25D<sub>3</sub> decreased despite no change in subjects&#x02019; sunlight exposure or diet.</p><p>These findings have considerable precedence; for example, decreased 25D<sub>3</sub> concentration after f4 weeks of supplementation with vitamin D<sub>2</sub> have been reported [<xref rid="B56" ref-type="bibr">56</xref>]. Furthermore, several studies from our group and others have shown that expression of CYP24A1 is increased by 1,25 D [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B57" ref-type="bibr">57</xref>&#x02013;<xref rid="B59" ref-type="bibr">59</xref>], that the ratio of 24,25D<sub>3</sub> to 25D<sub>3</sub> increases disproportionately in subjects with higher 25D<sub>3</sub> concentrations [<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B60" ref-type="bibr">60</xref>&#x02013;<xref rid="B65" ref-type="bibr">65</xref>], and that supplementing patients with vitamin D deficiency with vitamin D<sub>3</sub> results in increases in the ratio of 24,25D<sub>3</sub> to 25D<sub>3</sub> similar to the effects we observed in response to vitamin D<sub>2</sub> supplementation [<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B66" ref-type="bibr">66</xref>]. One note of significance: A previous study found that 12-week treatment with high-dose ergocalciferol resulted in significant increases in subjects&#x02019; FGF23 levels [<xref rid="B67" ref-type="bibr">67</xref>], and previous studies have suggested that FGF23 plays a role in regulation of CYP24A1. In our short-term treatment study, however, we observed no statistically significant changes in subjects&#x02019; FGF23 levels, thus the changes in 24,25D<sub>3</sub> metabolism and 24,25D<sub>3</sub> to 25D<sub>3</sub> ratio after ergocalciferol treatment could not be explained by changes in FGF23 [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>].</p><p>This study has several limitations. In contrast to our results (and those of Glendenning <italic>et al.</italic> [<xref rid="B51" ref-type="bibr">51</xref>]), two previous studies of subjects receiving 15 weeks or 1 year of vitamin D supplementation did not report significant changes in DBP concentrations [<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B70" ref-type="bibr">70</xref>]. Reasons for the discrepancy may be due to the fact that our study explored the acute effects of 2 weeks of vitamin D supplementation, whereas the other studies examined changes after longer periods of supplementation, after which feedback inhibitory mechanisms may have already normalized 1,25D signaling. Alternatively, differences may be due to our use of an LC-MS/MS assay to measure DBP, whereas these previous reports used various immunoassays. Second, after supplementation with vitamin D<sub>2</sub>, there were increases in concentrations of 1,25D, 25D, and 24,25D. Although we hypothesize that the changes in DBP are in response to increased activation of vitamin D receptor by 1,25D, it is possible that other vitamin D metabolites (<italic>e.g.</italic>, 25D or 24,25D) may be influencing DBP expression, because there is growing evidence that 24,25D may have its own physiologic activities [<xref rid="B71" ref-type="bibr">71</xref>]. It is also possible that a portion of the increase in 1,25D is due to the increase in DBP concentrations and not the reverse. To clarify these issues, future studies are needed to investigate whether supplementation with 1,25D directly causes similar changes in DBP expression. Third, the number of subjects in our study was relatively small, and the study design did not include placebo controls. Thus, although the effects seen in our subjects were substantial, the strength of our conclusions would be fortified by additional studies with larger numbers of subjects and the inclusion of placebo controls. It should also be noted that baseline average concentrations of DBP in our healthy subjects were lower than the DBP concentrations reported by others [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>]. The fact that we used a different calibrator for DBP than these past studies may explain these differences; furthermore, these previous studies used a polyclonal immunoassay that has been shown to produce measurements significantly higher than other validated assay methods [<xref rid="B73" ref-type="bibr">73</xref>]. Furthermore, because our study focused on changes in DBP concentrations within individuals after treatment, and not on differences in absolute DBP concentrations, differences in DBP concentrations compared with other assay methods should not alter the interpretation or significance of our results.</p><p>In conclusion, after supplementation with high doses of ergocalciferol (29.7 times the daily recommended supplement of 600 IU) among otherwise healthy subjects, a marked rise in 25D<sub>2</sub> concentrations and a 152% increase in total 25D concentrations were accompanied by a 39% rise in blood levels of DBP and a 36% rise in 24,25D levels. Together, the increases in DBP levels and CYP24A1 activity may serve as regulatory mechanisms meant to actively prevent excessive signaling and vitamin D receptor activation, and maintain minerals and respective hormones in homeostatic balance.</p></sec></body><back><fn-group content-type="abbreviations"><fn id="abbr" fn-type="abbr"><p>Abbreviations: <def-list><def-item><term id="G1">1,25D</term><def><p>1,25-dihydroxyvitamin D<sub>3</sub> plus 1,25-dihydroxyvitamin D<sub>2</sub></p></def></def-item><def-item><term id="G2">24,25D</term><def><p>24,25-dihydroxyvitamin D</p></def></def-item><def-item><term id="G3">24,25D<sub>2</sub></term><def><p>24,25-dihydroxyvitamin D<sub>2</sub></p></def></def-item><def-item><term id="G4">24,25D<sub>3</sub></term><def><p>24,25-dihydroxyvitamin D<sub>3</sub></p></def></def-item><def-item><term id="G5">25D</term><def><p>25-dihydroxyvitamin D</p></def></def-item><def-item><term id="G6">25D<sub>2</sub></term><def><p>25-hydroxyvitamin D<sub>2</sub></p></def></def-item><def-item><term id="G7">25D<sub>3</sub></term><def><p>25-hydroxyvitamin D<sub>3</sub></p></def></def-item><def-item><term id="G8">CYP24A1</term><def><p>25-hydroxyvitamin D 24-hydroxylase</p></def></def-item><def-item><term id="G9">DBP</term><def><p>vitamin D binding protein</p></def></def-item><def-item><term id="G10">FGF23</term><def><p>fibroblast growth factor-23</p></def></def-item><def-item><term id="G11">LC-MS/MS</term><def><p>liquid chromatography&#x02013;tandem mass spectrometry</p></def></def-item><def-item><term id="G12">PTH</term><def><p>parathyroid hormone.</p></def></def-item></def-list></p></fn></fn-group><ack><title>Acknowledgments</title><p>We thank Dr. Kathryn Lucchesi for critical reading and helpful editorial suggestions.</p></ack><ack><p content-type="financial-disclosure">A.B. is supported by Grant K08 HL121801 from the National Institutes of Health (NIH) and by American Diabetes Association Innovation Grant 1-15-IN-02. R.T. is supported by NIH Grants DK094872 and DK094486.</p><p>Author contributions: A.H.B., I.B., C.P., S.A.K., and R.I.T. designed the study and collected data. A.H.B., I.B., C.P., S.A.K., D.X., and R.I.T. analyzed and interpreted the data, and drafted the manuscript. A.H.B., I.B., S.A.K., and R.I.T. approved the final manuscript. A.H.B., I.B., and R.I.T. are accountable for all aspects of the work and are jointly responsible to ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p><p>Clinical trial registry: ClinicalTrials.gov no. NCT00742235 (registered 25 August 2008).</p><p>Disclosure Summary: The authors have nothing to disclose.</p></ack><ref-list><title>References and Notes</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Michos</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Post</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Astor</surname><given-names>B</given-names></name></person-group>
<article-title>25-hydroxyvitamin D levels and the risk of mortality in the general population</article-title>. <source>Arch Intern Med</source>. <year>2008</year>;<volume>168</volume>(<issue>15</issue>):<fpage>1629</fpage>&#x02013;<lpage>1637</lpage>.<pub-id pub-id-type="pmid">18695076</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cauley</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Lacroix</surname><given-names>AZ</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Horwitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Danielson</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Bauer</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stanczyk</surname><given-names>FZ</given-names></name>, <name name-style="western"><surname>LeBoff</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Wactawski-Wende</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sarto</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ockene</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>SR</given-names></name></person-group>
<article-title>Serum 25-hydroxyvitamin D concentrations and risk for hip fractures</article-title>. <source>Ann Intern Med</source>. <year>2008</year>;<volume>149</volume>(<issue>4</issue>):<fpage>242</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">18711154</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginde</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004</article-title>. <source>Arch Intern Med</source>. <year>2009</year>;<volume>169</volume>(<issue>6</issue>):<fpage>626</fpage>&#x02013;<lpage>632</lpage>.<pub-id pub-id-type="pmid">19307527</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wactawski-Wende</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kotchen</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Assaf</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Brunner</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>O&#x02019;Sullivan</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Margolis</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Ockene</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pottern</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Prentice</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rohan</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Sarto</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Stefanick</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Van Horn</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Whitlock</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bassford</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Beresford</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Bonds</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Brzyski</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Caan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chlebowski</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Cochrane</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Garland</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gass</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hays</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Heiss</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hendrix</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Howard</surname><given-names>BV</given-names></name>, <name name-style="western"><surname>Hsia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hubbell</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Judd</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kooperberg</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Kuller</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>LaCroix</surname><given-names>AZ</given-names></name>, <name name-style="western"><surname>Lane</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Langer</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Lasser</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Limacher</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Manson</surname><given-names>JE</given-names></name>; <collab>Women&#x02019;s Health Initiative Investigators</collab></person-group>
<article-title>Calcium plus vitamin D supplementation and the risk of colorectal cancer</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>7</issue>):<fpage>684</fpage>&#x02013;<lpage>696</lpage>.<pub-id pub-id-type="pmid">16481636</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Booth</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Jacques</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Ingelsson</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lanier</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>D&#x02019;Agostino</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vasan</surname><given-names>RS</given-names></name></person-group>
<article-title>Vitamin D deficiency and risk of cardiovascular disease</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>117</volume>(<issue>4</issue>):<fpage>503</fpage>&#x02013;<lpage>511</lpage>.<pub-id pub-id-type="pmid">18180395</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Lloyd-Jones</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Thadhani</surname><given-names>RI</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Deraska</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Kitch</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Vamvakas</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Dick</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Prince</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Finkelstein</surname><given-names>JS</given-names></name></person-group>
<article-title>Hypovitaminosis D in medical inpatients</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>338</volume>(<issue>12</issue>):<fpage>777</fpage>&#x02013;<lpage>783</lpage>.<pub-id pub-id-type="pmid">9504937</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heaney</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>CM</given-names></name></person-group>
<article-title>Calcium and vitamin D</article-title>. <source>Endocrinol Metab Clin North Am</source>. <year>2003</year>;<volume>32</volume>(<issue>1</issue>):<fpage>181</fpage>&#x02013;<lpage>194, vii&#x02013;viii</lpage>
<comment>(vii-viii)</comment>.<pub-id pub-id-type="pmid">12699298</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villareal</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Civitelli</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chines</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Avioli</surname><given-names>LV</given-names></name></person-group>
<article-title>Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1991</year>;<volume>72</volume>(<issue>3</issue>):<fpage>628</fpage>&#x02013;<lpage>634</lpage>.<pub-id pub-id-type="pmid">1997517</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blank</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Scanlon</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Sinks</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Lett</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Falk</surname><given-names>H</given-names></name></person-group>
<article-title>An outbreak of hypervitaminosis D associated with the overfortification of milk from a home-delivery dairy</article-title>. <source>Am J Public Health</source>. <year>1995</year>;<volume>85</volume>(<issue>5</issue>):<fpage>656</fpage>&#x02013;<lpage>659</lpage>.<pub-id pub-id-type="pmid">7733425</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holick</surname><given-names>MF</given-names></name></person-group>
<article-title>Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease</article-title>. <source>Am J Clin Nutr</source>. <year>2004</year>; <volume>80</volume>(<issue>6</issue>, <supplement>Suppl</supplement>):<fpage>1678S</fpage>&#x02013;<lpage>1688S</lpage>.<pub-id pub-id-type="pmid">15585788</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powe</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Wenger</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zonderman</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Berg</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Nalls</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tamez</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bhan</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Karumanchi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Powe</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Thadhani</surname><given-names>R</given-names></name></person-group>
<article-title>Vitamin D-binding protein and vitamin D status of black Americans and white Americans</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>21</issue>):<fpage>1991</fpage>&#x02013;<lpage>2000</lpage>.<pub-id pub-id-type="pmid">24256378</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Rafison</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Witzel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Reyes</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Shieh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chun</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zavala</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hewison</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>PT</given-names></name></person-group>
<article-title>Regulation of the extrarenal CYP27B1-hydroxylase</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2014</year>;<volume>144</volume>(<issue>Pt A</issue>):<fpage>22</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">24388948</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranch</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Portale</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Perwad</surname><given-names>F</given-names></name></person-group>
<article-title>Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice</article-title>. <source>J Bone Miner Res</source>. <year>2011</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1883</fpage>&#x02013;<lpage>1890</lpage>.<pub-id pub-id-type="pmid">21472778</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akeno</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Saikatsu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kawane</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Horiuchi</surname><given-names>N</given-names></name></person-group>
<article-title>Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3</article-title>. <source>Endocrinology</source>. <year>1997</year>;<volume>138</volume>(<issue>6</issue>):<fpage>2233</fpage>&#x02013;<lpage>2240</lpage>.<pub-id pub-id-type="pmid">9165006</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bikle</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Gee</surname><given-names>E</given-names></name></person-group>
<article-title>Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes</article-title>. <source>Endocrinology</source>. <year>1989</year>;<volume>124</volume>(<issue>2</issue>):<fpage>649</fpage>&#x02013;<lpage>654</lpage>.<pub-id pub-id-type="pmid">2463902</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Lauridsen</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Suon</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zella</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Pike</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Modlin</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Martineau</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Wilkinson</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hewison</surname><given-names>M</given-names></name></person-group>
<article-title>Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2010</year>;<volume>95</volume>(<issue>7</issue>):<fpage>3368</fpage>&#x02013;<lpage>3376</lpage>.<pub-id pub-id-type="pmid">20427486</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddad</surname><given-names>JG</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Transport of vitamin D metabolites</article-title>. <source>Clin Orthop Relat Res</source>. <year>1979</year>;(<issue>142</issue>):<fpage>249</fpage>&#x02013;<lpage>261</lpage>.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Prosser</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Kaufmann</surname><given-names>M</given-names></name></person-group>
<article-title>25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D</article-title>. <source>Arch Biochem Biophys</source>. <year>2012</year>;<volume>523</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">22100522</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Nishimura</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nagai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ohyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Noshiro</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Okuda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Suda</surname><given-names>T</given-names></name></person-group>
<article-title>Parathyroid hormone inhibits 25-hydroxyvitamin D3-24-hydroxylase mRNA expression stimulated by 1 alpha,25-dihydroxyvitamin D3 in rat kidney but not in intestine</article-title>. <source>J Biol Chem</source>. <year>1992</year>;<volume>267</volume>(<issue>19</issue>):<fpage>13757</fpage>&#x02013;<lpage>13762</lpage>.<pub-id pub-id-type="pmid">1618870</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bikle</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Gee</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Halloran</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kowalski</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Ryzen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>JG</given-names></name></person-group>
<article-title>Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1986</year>;<volume>63</volume>(<issue>4</issue>):<fpage>954</fpage>&#x02013;<lpage>959</lpage>.<pub-id pub-id-type="pmid">3745408</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carpenter</surname><given-names>TO</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Parra</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ellis</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Simpson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Balko</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>BY</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>DE</given-names></name></person-group>
<article-title>Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers</article-title>. <source>J Bone Miner Res</source>. <year>2013</year>;<volume>28</volume>(<issue>1</issue>):<fpage>213</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">22887780</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Peercy</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Orwoll</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Nielson</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Hewison</surname><given-names>M</given-names></name></person-group>
<article-title>Vitamin D and DBP: The free hormone hypothesis revisited</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2014</year>;<volume>144</volume>(<issue>Pt A</issue>):<fpage>132</fpage>&#x02013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">24095930</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlsson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Osmancevic</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jansson</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hulth&#x000e9;n</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Holm&#x000e4;ng</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Larsson</surname><given-names>I</given-names></name></person-group>
<article-title>Increased vitamin D-binding protein and decreased free 25(OH)D in obese women of reproductive age</article-title>. <source>Eur J Nutr</source>. <year>2014</year>;<volume>53</volume>(<issue>1</issue>):<fpage>259</fpage>&#x02013;<lpage>267</lpage>.<pub-id pub-id-type="pmid">23604494</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safadi</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Thornton</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Magiera</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hollis</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Gentile</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Liebhaber</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Cooke</surname><given-names>NE</given-names></name></person-group>
<article-title>Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein</article-title>. <source>J Clin Invest</source>. <year>1999</year>;<volume>103</volume>(<issue>2</issue>):<fpage>239</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">9916136</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lizaola</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kane</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Weyland</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Terrault</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Stotland</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bikle</surname><given-names>D</given-names></name></person-group>
<article-title>Variability in free 25(OH) vitamin D levels in clinical populations</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2014</year>;<volume>144</volume>(<issue>Pt A</issue>):<fpage>156</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">24240067</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosner</surname><given-names>W</given-names></name></person-group>
<article-title>Sex steroids and the free hormone hypothesis</article-title>. <source>Cell</source>. <year>2006</year>;<volume>124</volume>(<issue>3</issue>):<fpage>455</fpage>&#x02013;<lpage>456, author reply 456&#x02013;457</lpage>.<pub-id pub-id-type="pmid">16469688</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>JS</given-names></name></person-group>
<article-title>&#x0201c;Bound&#x0201d; to work: the free hormone hypothesis revisited</article-title>. <source>Cell</source>. <year>2005</year>;<volume>122</volume>(<issue>5</issue>):<fpage>647</fpage>&#x02013;<lpage>649</lpage>.<pub-id pub-id-type="pmid">16143095</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Midgley</surname><given-names>JE</given-names></name></person-group>
<article-title>The free thyroid hormone hypothesis and measurement of free hormones</article-title>. <source>Clin Chem</source>. <year>1993</year>;<volume>39</volume>(<issue>6</issue>):<fpage>1342</fpage>&#x02013;<lpage>1344</lpage>.<pub-id pub-id-type="pmid">8504547</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bikle</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Siiteri</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Ryzen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>JG</given-names></name></person-group>
<article-title>Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1985</year>;<volume>61</volume>(<issue>5</issue>):<fpage>969</fpage>&#x02013;<lpage>975</lpage>.<pub-id pub-id-type="pmid">3840175</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnaud</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Constans</surname><given-names>J</given-names></name></person-group>
<article-title>Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP)</article-title>. <source>Hum Genet</source>. <year>1993</year>;<volume>92</volume>(<issue>2</issue>):<fpage>183</fpage>&#x02013;<lpage>188</lpage>.<pub-id pub-id-type="pmid">8370586</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lizaola</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kane</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Markova</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Weyland</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Terrault</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Stotland</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bikle</surname><given-names>D</given-names></name></person-group>
<article-title>A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2014</year>;<volume>99</volume>(<issue>5</issue>):<fpage>1631</fpage>&#x02013;<lpage>1637</lpage>.<pub-id pub-id-type="pmid">24483159</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Prosser</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Kaufmann</surname><given-names>M</given-names></name></person-group>
<article-title>Cytochrome P450-mediated metabolism of vitamin D</article-title>. <source>J Lipid Res</source>. <year>2014</year>;<volume>55</volume>(<issue>1</issue>):<fpage>13</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">23564710</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moutos</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zacur</surname><given-names>H</given-names></name></person-group>
<article-title>The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial</article-title>. <source>Contraception</source>. <year>1995</year>;<volume>52</volume>(<issue>2</issue>):<fpage>105</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">8536446</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thijssen</surname><given-names>JH</given-names></name></person-group>
<article-title>Hormonal and nonhormonal factors affecting sex hormone-binding globulin levels in blood</article-title>. <source>Ann N Y Acad Sci</source>. <year>1988</year>;<volume>538</volume>:<fpage>280</fpage>&#x02013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">3056190</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Bosch</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Greene</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rogers</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>D</given-names></name>; <collab>Modification of Diet in Renal Disease Study Group</collab></person-group>
<article-title>A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation</article-title>. <source>Ann Intern Med</source>. <year>1999</year>;<volume>130</volume>(<issue>6</issue>):<fpage>461</fpage>&#x02013;<lpage>470</lpage>.<pub-id pub-id-type="pmid">10075613</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhan</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name>., <name name-style="western"><surname>Wenger</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ricciardi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Borregaard</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Thadhani</surname><given-names>R</given-names></name></person-group>
<article-title>Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults</article-title>. <source>J Allergy Clin Immunol</source>. <year>2011</year>;<volume>127</volume>(<issue>5</issue>):<fpage>1302</fpage>&#x02013;<lpage>1304 e1301</lpage>.<pub-id pub-id-type="pmid">21310475</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Powe</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Wenger</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ortiz</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zonderman</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Suntharalingam</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lucchesi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Powe</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Karumanchi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Thadhani</surname><given-names>RI</given-names></name></person-group>
<article-title>24,25-Dihydroxyvitamin d3 and vitamin D status of community-dwelling black and white Americans</article-title>. <source>Clin Chem</source>. <year>2015</year>;<volume>61</volume>(<issue>6</issue>):<fpage>877</fpage>&#x02013;<lpage>884</lpage>.<pub-id pub-id-type="pmid">25922442</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valcour</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zierold</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Podgorski</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>GT</given-names></name>, <name name-style="western"><surname>Wall</surname><given-names>JV</given-names></name>, <name name-style="western"><surname>DeLuca</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Bonelli</surname><given-names>F</given-names></name></person-group>
<article-title>A novel, fully-automated, chemiluminescent assay for the detection of 1,25-dihydroxyvitamin D in biological samples</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2016</year>;<volume>164</volume>:<fpage>120</fpage>&#x02013;<lpage>126</lpage>.<pub-id pub-id-type="pmid">26303747</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powe</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Ricciardi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Berg</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Erdenesanaa</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Collerone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ankers</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wenger</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Karumanchi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Thadhani</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bhan</surname><given-names>I</given-names></name></person-group>
<article-title>Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship</article-title>. <source>J Bone Miner Res</source>. <year>2011</year>;<volume>26</volume>(<issue>7</issue>):<fpage>1609</fpage>&#x02013;<lpage>1616</lpage>.<pub-id pub-id-type="pmid">21416506</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Lutsey</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Misialek</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Laha</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Selvin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Eckfeldt</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Hoofnagle</surname><given-names>AN</given-names></name></person-group>
<article-title>Measurement by a novel LC-MS/MS methodology reveals similar serum concentrations of vitamin D-binding protein in blacks and whites</article-title>. <source>Clin Chem</source>. <year>2016</year>;<volume>62</volume>(<issue>1</issue>):<fpage>179</fpage>&#x02013;<lpage>187</lpage>.<pub-id pub-id-type="pmid">26453697</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enko</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fridrich</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rezanka</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Stolba</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ernst</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wendler</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Fabian</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hauptlorenz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Halwachs-Baumann</surname><given-names>G</given-names></name></person-group>
<article-title>25-hydroxy-Vitamin D status: limitations in comparison and clinical interpretation of serum-levels across different assay methods</article-title>. <source>Clin Lab</source>. <year>2014</year>;<volume>60</volume>(<issue>9</issue>):<fpage>1541</fpage>&#x02013;<lpage>1550</lpage>.<pub-id pub-id-type="pmid">25291951</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Soldo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Herrmann</surname><given-names>M</given-names></name></person-group>
<article-title>25-Hydroxyvitamin D testing: challenging the performance of current automated immunoassays</article-title>. <source>Clin Chem Lab Med</source>. <year>2012</year>;<volume>50</volume>(<issue>11</issue>):<fpage>1953</fpage>&#x02013;<lpage>1963</lpage>.<pub-id pub-id-type="pmid">23113977</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Saw</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sahabdeen</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>Tey</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Sethi</surname><given-names>SK</given-names></name></person-group>
<article-title>Current 25-hydroxyvitamin D assays: do they pass the test?</article-title>
<source>Clin Chim Acta</source>. <year>2012</year>;<volume>413</volume>(<issue>13-14</issue>):<fpage>1127</fpage>&#x02013;<lpage>1134</lpage>.<pub-id pub-id-type="pmid">22465235</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>GD</given-names></name></person-group>
<article-title>Accuracy of 25-hydroxyvitamin D assays: confronting the issues</article-title>. <source>Curr Drug Targets</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">20795940</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Manson</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Abrams</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Aloia</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Brannon</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Clinton</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Gallagher</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Gallo</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kovacs</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Mayne</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Rosen</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Shapses</surname><given-names>SA</given-names></name></person-group>
<article-title>The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">21118827</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouillon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>van Baelen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>de Moor</surname><given-names>P</given-names></name></person-group>
<article-title>Comparative study of the affinity of the serum vitamin D-binding protein</article-title>. <source>J Steroid Biochem</source>. <year>1980</year>;<volume>13</volume>(<issue>9</issue>):<fpage>1029</fpage>&#x02013;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">6893475</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Peercy</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Hewison</surname><given-names>M</given-names></name></person-group>
<article-title>Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e30773</fpage>.<pub-id pub-id-type="pmid">22292037</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nykjaer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dragun</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Walther</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Vorum</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jacobsen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Herz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Melsen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Christensen</surname><given-names>EI</given-names></name>, <name name-style="western"><surname>Willnow</surname><given-names>TE</given-names></name></person-group>
<article-title>An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3</article-title>. <source>Cell</source>. <year>1999</year>;<volume>96</volume>(<issue>4</issue>):<fpage>507</fpage>&#x02013;<lpage>515</lpage>.<pub-id pub-id-type="pmid">10052453</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bikle</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Gee</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Halloran</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>JG</given-names></name></person-group>
<article-title>Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease</article-title>. <source>J Clin Invest</source>. <year>1984</year>;<volume>74</volume>(<issue>6</issue>):<fpage>1966</fpage>&#x02013;<lpage>1971</lpage>.<pub-id pub-id-type="pmid">6549014</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pop</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Shapses</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group>
<article-title>Vitamin D-binding protein in healthy pre- and postmenopausal women: relationship with estradiol concentrations</article-title>. <source>Endocr Pract</source>. <year>2015</year>;<volume>21</volume>(<issue>8</issue>):<fpage>936</fpage>&#x02013;<lpage>942</lpage>.<pub-id pub-id-type="pmid">26121448</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glendenning</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Chew</surname><given-names>GT</given-names></name>, <name name-style="western"><surname>Inderjeeth</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Taranto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fraser</surname><given-names>WD</given-names></name></person-group>
<article-title>Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol</article-title>. <source>Bone</source>. <year>2013</year>;<volume>56</volume>(<issue>2</issue>):<fpage>271</fpage>&#x02013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">23792937</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouillon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Van Assche</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Van Baelen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Heyns</surname><given-names>W</given-names></name>, <name name-style="western"><surname>De Moor</surname><given-names>P</given-names></name></person-group>
<article-title>Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration</article-title>. <source>J Clin Invest</source>. <year>1981</year>;<volume>67</volume>(<issue>3</issue>):<fpage>589</fpage>&#x02013;<lpage>596</lpage>.<pub-id pub-id-type="pmid">6894152</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Hoof</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>de S&#x000e9;vaux</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>van Baelen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Swinkels</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Klipping</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Sweep</surname><given-names>CG</given-names></name></person-group>
<article-title>Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding</article-title>. <source>Eur J Endocrinol</source>. <year>2001</year>;<volume>144</volume>(<issue>4</issue>):<fpage>391</fpage>&#x02013;<lpage>396</lpage>.<pub-id pub-id-type="pmid">11275949</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Assar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Harnpanich</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bouillon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lambrechts</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Prentice</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schoenmakers</surname><given-names>I</given-names></name></person-group>
<article-title>25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2014</year>;<volume>99</volume>(<issue>9</issue>):<fpage>3373</fpage>&#x02013;<lpage>3381</lpage>.<pub-id pub-id-type="pmid">24885631</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wiesner</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Go</surname><given-names>VL</given-names></name></person-group>
<article-title>Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects</article-title>. <source>Am J Physiol</source>. <year>1982</year>;<volume>243</volume>(<issue>5</issue>):<fpage>E370</fpage>&#x02013;<lpage>E374</lpage>.<pub-id pub-id-type="pmid">6753604</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itkonen</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Skaffari</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Saaristo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Saarnio</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Erkkola</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jakobsen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cashman</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Lamberg-Allardt</surname><given-names>C</given-names></name></person-group>
<article-title>Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women</article-title>. <source>Br J Nutr</source>. <year>2016</year>;<volume>115</volume>(<issue>7</issue>):<fpage>1232</fpage>&#x02013;<lpage>1239</lpage>.<pub-id pub-id-type="pmid">26864127</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Quach</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Vieth</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pang</surname><given-names>KS</given-names></name></person-group>
<article-title>Temporal changes in tissue 1&#x003b1;,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2013</year>;<volume>304</volume>(<issue>9</issue>):<fpage>E977</fpage>&#x02013;<lpage>E989</lpage>.<pub-id pub-id-type="pmid">23482451</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seth-Vollenweider</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Joshi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dhawan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sif</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Christakos</surname><given-names>S</given-names></name></person-group>
<article-title>Novel mechanism of negative regulation of 1,25-dihydroxyvitamin D3-induced 25-hydroxyvitamin D3 24-hydroxylase (Cyp24a1) transcription: epigenetic modification involving cross-talk between protein-arginine methyltransferase 5 and the SWI/SNF complex</article-title>. <source>J Biol Chem</source>. <year>2014</year>;<volume>289</volume>(<issue>49</issue>):<fpage>33958</fpage>&#x02013;<lpage>33970</lpage>.<pub-id pub-id-type="pmid">25324546</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petkovich</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Melnick</surname><given-names>J</given-names></name>, <name name-style="western"><surname>White</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tabash</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Strugnell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bishop</surname><given-names>CW</given-names></name></person-group>
<article-title>Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2015</year>;<volume>148</volume>:<fpage>283</fpage>&#x02013;<lpage>289</lpage>.<pub-id pub-id-type="pmid">25446887</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Boer</surname><given-names>IH</given-names></name>, <name name-style="western"><surname>Sachs</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Chonchol</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Himmelfarb</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hoofnagle</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Ix</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Kremsdorf</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Mehrotra</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Robinson-Cohen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Siscovick</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Steffes</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Tracy</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Kestenbaum</surname><given-names>B</given-names></name></person-group>
<article-title>Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials</article-title>. <source>Am J Kidney Dis</source>. <year>2014</year>;<volume>64</volume>(<issue>2</issue>):<fpage>187</fpage>&#x02013;<lpage>197</lpage>.<pub-id pub-id-type="pmid">24703961</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gallagher</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Peacock</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schlingmann</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Konrad</surname><given-names>M</given-names></name>, <name name-style="western"><surname>DeLuca</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Sigueiro</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lopez</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mourino</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Maestro</surname><given-names>M</given-names></name>, <name name-style="western"><surname>St-Arnaud</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Finkelstein</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>G</given-names></name></person-group>
<article-title>Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2014</year>;<volume>99</volume>(<issue>7</issue>):<fpage>2567</fpage>&#x02013;<lpage>2574</lpage>.<pub-id pub-id-type="pmid">24670084</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hanwell</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Schnabl</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yazdanpanah</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kimball</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sidhom</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Rousseau</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Vieth</surname><given-names>R</given-names></name></person-group>
<article-title>The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2011</year>;<volume>126</volume>(<issue>3-5</issue>):<fpage>72</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">21605672</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burild</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Frandsen</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Jakobsen</surname><given-names>J</given-names></name></person-group>
<article-title>Simultaneous quantification of vitamin D<sub>3</sub>, 25-hydroxyvitamin D<sub>3</sub> and 24,25-dihydroxyvitamin D<sub>3</sub> in human serum by LC-MS/MS</article-title>. <source>Scand J Clin Lab Invest</source>. <year>2014</year>;<volume>74</volume>(<issue>5</issue>):<fpage>418</fpage>&#x02013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">24749986</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cashman</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Galvin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Merkel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kaufmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hoofnagle</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Sempos</surname><given-names>CT</given-names></name></person-group>
<article-title>Significance of serum 24,25-dihydroxyvitamin D in the assessment of vitamin D status: a double-edged sword?</article-title>
<source>Clin Chem</source>. <year>2015</year>;<volume>61</volume>(<issue>4</issue>):<fpage>636</fpage>&#x02013;<lpage>645</lpage>.<pub-id pub-id-type="pmid">25710460</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edouard</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Husseini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Glorieux</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>Rauch</surname><given-names>F</given-names></name></person-group>
<article-title>Serum 24,25-dihydroxyvitamin D concentrations in osteogenesis imperfecta: relationship to bone parameters</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2012</year>;<volume>97</volume>(<issue>4</issue>):<fpage>1243</fpage>&#x02013;<lpage>1249</lpage>.<pub-id pub-id-type="pmid">22319032</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cashman</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>O&#x02019;Donovan</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Kinsella</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Galvin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kiely</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Seamans</surname><given-names>KM</given-names></name></person-group>
<article-title>Dietary calcium does not interact with vitamin D<sub>3</sub> in terms of determining the response and catabolism of serum 25-hydroxyvitamin D during winter in older adults</article-title>. <source>Am J Clin Nutr</source>. <year>2014</year>;<volume>99</volume>(<issue>6</issue>):<fpage>1414</fpage>&#x02013;<lpage>1423</lpage>.<pub-id pub-id-type="pmid">24695896</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnett-Bowie</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Leder</surname><given-names>BZ</given-names></name>, <name name-style="western"><surname>Henao</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Baldwin</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Hayden</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Finkelstein</surname><given-names>JS</given-names></name></person-group>
<article-title>Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2012</year>;<volume>7</volume>(<issue>4</issue>):<fpage>624</fpage>&#x02013;<lpage>631</lpage>.<pub-id pub-id-type="pmid">22300739</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Miao</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>St-Arnaud</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Petkovich</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Goltzman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Karaplis</surname><given-names>AC</given-names></name></person-group>
<article-title>CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders</article-title>. <source>J Clin Invest</source>. <year>2016</year>;<volume>126</volume>(<issue>2</issue>):<fpage>667</fpage>&#x02013;<lpage>680</lpage>.<pub-id pub-id-type="pmid">26784541</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dusso</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>M</given-names></name></person-group>
<article-title>Enhanced induction of Cyp24a1 by FGF23 but low serum 24,25-dihydroxyvitamin D in CKD: implications for therapy</article-title>. <source>Kidney Int</source>. <year>2012</year>;<volume>82</volume>(<issue>10</issue>):<fpage>1046</fpage>&#x02013;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">23128114</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sollid</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Hutchinson</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Berg</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Fuskevag</surname><given-names>OM</given-names></name>, <name name-style="western"><surname>Figenschau</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Thorsby</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Jorde</surname><given-names>R</given-names></name></person-group>
<article-title>Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D</article-title>. <source>Eur J Endocrinol</source>. <year>2016</year>;<volume>174</volume>(<issue>4</issue>):<fpage>445</fpage>&#x02013;<lpage>452</lpage>.<pub-id pub-id-type="pmid">26733479</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Meijden</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lips</surname><given-names>P</given-names></name>, <name name-style="western"><surname>van Driel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Heijboer</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Schulten</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>den Heijer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bravenboer</surname><given-names>N</given-names></name></person-group>
<article-title>Primary human osteoblasts in response to 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>10</issue>):<fpage>e110283</fpage>.<pub-id pub-id-type="pmid">25329305</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrone</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Weir</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Steffen</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Gaziano</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Djouss&#x000e9;</surname><given-names>L</given-names></name></person-group>
<article-title>Plasma vitamin D-binding protein and risk of heart failure in male physicians</article-title>. <source>Am J Cardiol</source>. <year>2013</year>;<volume>112</volume>(<issue>6</issue>):<fpage>827</fpage>&#x02013;<lpage>830</lpage>.<pub-id pub-id-type="pmid">23735647</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutsey</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Parrinello</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Misialek</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Hoofnagle</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Henderson</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Laha</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Michos</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Eckfeldt</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Selvin</surname><given-names>E</given-names></name></person-group>
<article-title>Short-term variability of Vitamin D-related biomarkers</article-title>. <source>Clin Chem</source>. <year>2016</year>;<volume>62</volume>(<issue>12</issue>):<fpage>1647</fpage>&#x02013;<lpage>1653</lpage>.<pub-id pub-id-type="pmid">27694392</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denburg</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Hoofnagle</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Sayed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>J</given-names></name>, <name name-style="western"><surname>de Boer</surname><given-names>IH</given-names></name>, <name name-style="western"><surname>Appel</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Durazo-Arvizu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Whitehead</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Feldman</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>MB</given-names></name>, <collab>Chronic Renal Insufficiency Cohort study investigators</collab></person-group>
<article-title>Comparison of two ELISA methods and mass spectrometry for measurement of vitamin D-binding protein: implications for the assessment of bioavailable vitamin D concentrations across genotypes</article-title>. <source>J Bone Miner Res</source>. <year>2016</year>;<volume>31</volume>:<fpage>1128</fpage>&#x02013;<lpage>1136</lpage>.<pub-id pub-id-type="pmid">27250744</pub-id></mixed-citation></ref></ref-list></back></article>